ConductScience.org, home

Paper33142138

Expression of NK cell receptor ligands in primary colorectal cancer tissue in relation to the phenotype of circulating NK- and NKT cells, and clinical outcome.

Krijgsman D and 8 others. Mol Immunol, 2020. Cited by 22 papers, by iCite.

Cite this record

ConductScience Library. Expression of NK cell receptor ligands in primary colorectal cancer tissue in relation to the phenotype of circulating NK- and NKT cells, and clinical outcome. Papers, record 33142138. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33142138

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Expression of NK cell receptor ligands in primary colorectal cancer tissue in relation to the phenotype of circulating NK- and NKT cells, and clinical outcome.
PubMed
Journal
Mol Immunol
PubMed
Year
2020
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
22
iCite
Relative citation ratio, by iCite
0.87
iCite
Revised in PubMed
2021-01-25
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Krijgsman DDaniëlle
2Roelands JJessica
3Andersen MNMorten N
4Wieringa CHLACornelia H L A
5Tollenaar RAEMRob A E M
6Hendrickx WWouter
7Bedognetti DDavide
8Hokland MMarianne
9Kuppen PJKPeter J K

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Colorectal NeoplasmsMajor topic
Killer Cells, NaturalMajor topic
Natural Killer T-CellsMajor topic
Receptors, Natural Killer CellMajor topic
Adult
Aged
Aged, 80 and over
Disease-Free Survival
Female
Galectin 3
Histocompatibility Antigens Class I
Humans
Intracellular Signaling Peptides and Proteins
Ligands
Male
Middle Aged
Phenotype
Proliferating Cell Nuclear Antigen

Source PubMed

Download CSV of topics

Cited by20

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 22 citations.

PMIDTitleJournalYearIn PapersSource
42985438Viruses in the tumor immune microenvironment: implications for immunotherapy.Front Immunol2026https://conductscience.org/library/papers/42985438PubMed
42902385Epigenetic modulation of NKG2D ligands enhances NKG2D-CAR T cell efficacy in neuroblastoma.J Transl Med2026https://conductscience.org/library/papers/42902385PubMed
42807766Prognostic value of neuro-related genes in colorectal cancer and their potential implications for immunotherapy.J Cancer2026https://conductscience.org/library/papers/42807766PubMed
42792652The Galectin Family in Colorectal Cancer: Integrating Molecular Mechanisms with Diagnostic, Prognostic, and Therapeutic Perspectives.Biomedicines2026https://conductscience.org/library/papers/42792652PubMed
42373129Lenalidomide boosts CD1d-Vδ2 bispecific antibody-engaged Vγ9Vδ2-T cell effector functions via CD28, Notch signaling and IL-2 release.J Immunother Cancer2026https://conductscience.org/library/papers/42373129PubMed
41516021The Need for a Systems Biology Approach in Cancer Explained.Int J Mol Sci2025https://conductscience.org/library/papers/41516021PubMed
40583406NKT cells-a generalist in disease treatment and a new key to unlock immunotherapy.Immunotherapy2025https://conductscience.org/library/papers/40583406PubMed
40371166The role of glycan-lectin interactions in the tumor microenvironment: immunosuppression regulators of colorectal cancer.Am J Cancer Res2025https://conductscience.org/library/papers/40371166PubMed
39920524Integration of single-cell and bulk RNA-sequencing data to construct and validate a signature based on NK cell marker genes to predict immunotherapy response and prognosis in colorectal cancer.Discov Oncol2025https://conductscience.org/library/papers/39920524PubMed
38836911Urinary dipeptidase 1 and trefoil factor 1 are promising biomarkers for early diagnosis of colorectal cancer.J Gastroenterol2024https://conductscience.org/library/papers/38836911PubMed
38486782CAR-NK cells in combination therapy against cancer: A potential paradigm.Heliyon2024https://conductscience.org/library/papers/38486782PubMed
38455977Circulation immune cell landscape in canonical pathogenesis of colorectal adenocarcinoma by CyTOF analysis.iScience2024https://conductscience.org/library/papers/38455977PubMed
38201234Can Galectin-3 Be a Novel Biomarker in Chronic Lymphocytic Leukemia?Cells2023https://conductscience.org/library/papers/38201234PubMed
37322531Immune profile of primary and recurrent epithelial ovarian cancer cases indicates immune suppression, a major cause of progression and relapse of ovarian cancer.J Ovarian Res2023https://conductscience.org/library/papers/37322531PubMed
36980678NKG2D Fine-Tunes the Local Inflammatory Response in Colorectal Cancer.Cancers (Basel)2023https://conductscience.org/library/papers/36980678PubMed
36436018PD-1 expression, among other immune checkpoints, on tumor-infiltrating NK and NKT cells is associated with longer disease-free survival in treatment-naïve CRC patients.Cancer Immunol Immunother2023https://conductscience.org/library/papers/36436018PubMed
35887206NK Cells and Other Cytotoxic Innate Lymphocytes in Colorectal Cancer Progression and Metastasis.Int J Mol Sci2022https://conductscience.org/library/papers/35887206PubMed
35741218Circulating Lymphocytes Reflect the Local Immune Response in Patients with Colorectal Carcinoma.Diagnostics (Basel)2022https://conductscience.org/library/papers/35741218PubMed
34925375The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer.Front Immunol2021https://conductscience.org/library/papers/34925375PubMed
34858978Cross-Talk Between Tumor Cells Undergoing Epithelial to Mesenchymal Transition and Natural Killer Cells in Tumor Microenvironment in Colorectal Cancer.Front Cell Dev Biol2021https://conductscience.org/library/papers/34858978PubMed

Download CSV of cited by

Genes8

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD1D912PubTator's text mininghttps://conductscience.org/library/genes/912NCBI Gene
HLA-E3133PubTator's text mininghttps://conductscience.org/library/genes/3133NCBI Gene
KLRD13824PubTator's text mininghttps://conductscience.org/library/genes/3824NCBI Gene
LGALS33958PubTator's text mininghttps://conductscience.org/library/genes/3958NCBI Gene
PCNA5111PubTator's text mininghttps://conductscience.org/library/genes/5111NCBI Gene
RAET1G353091PubTator's text mininghttps://conductscience.org/library/genes/353091NCBI Gene
ULBP180329PubTator's text mininghttps://conductscience.org/library/genes/80329NCBI Gene
ULBP280328PubTator's text mininghttps://conductscience.org/library/genes/80328NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33142138

GET https://conductscience.org/api/papers/v1/33142138/authors